# An Emerging Role of Long Noncoding RNAs as Novel Biomarkers for Breast Cancer Metastasis
## 5 Potential lncRNA-Based Biomarkers
### Other Potential lncRNA-Based Biomarkers Involved in the Metastatic Progression of Breast Cancer
\begin{table}
\begin{tabular}{c c c c c c c} \hline
**Studied** & **Authors, Year** & **Study Group** & **Study Material** & **IncRNA Change** & **Diagnostic Usefulness** & **References** \\ \hline HOTAIR & [PERSON] et al. (2015) & BC patients (n = 24) for the discovery; BC patients (n = 76) for validation & Serum & Upregulated & AUC: 0.799 & [34] \\ \hline MALAT1 & [PERSON] et al. (2016) & BC patients (n = 78); MDA-MB-231 cell line & Cancerous tissue samples; adjacent no-tumor samples; cell line & Upregulated & AUC: 0.833 & [41] \\ \hline MALAT1 & [PERSON] et al. (2015) & BC patients (n = 78); MDA-MB-231, MDA-MB-453 cell lines & Cancerous tissue samples; adjacent no-tumor samples; cell lines & Strong correlation with axillary LNM & [44] \\ \hline BANCR & [PERSON] et al. (2018) & BC patients (n = 65); MCF-7, MDA-MB-231, SKBR3, BT-20, MCF-10A cell lines & Cancerous tissue samples; adjacent no-tumor samples; cell lines & Larger tumor size, LNM, advanced TNM stage. & [46] \\ \hline NEAT1 & [PERSON] et al. (2019) & BC patients (n = 179) and normal controls (n = 192); MDA-MB-231 cell line & Serum; cell line & Upregulated & Particularly high expression in TNBC. & [48] \\ \hline H19 & [PERSON] et al. (2020) & BC patients (n = 50), BBD patients (n = 50), healthy volunteers (n = 50) & Serum & Upregulated & AUC: 0.807 & [58] \\ \hline GAS5 & [PERSON] et al. (2020) & BC patients (n = 50), non-cancer patients with at least one BC risk factor (n = 50), and healthy volunteers (n = 65) & Plasma & Downregulated & AUC: 0.754 & [65] \\ \hline \end{tabular}
\end{table} 
Table 1: Summary of the Most Relevant Studies on lncRNA-Based Biomarkers in Breast Cancer. \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline
**Studied** & **Authors, Year** & **Study Group** & **Study Material** & **IncRNA** & **Diagnostic** & **References** \\
**IncRNA** & & & & & **Change** & **Usefulness** & **References** \\ \hline HEIH & [PERSON] et al. & BC patients (n = 160), & Cancerous & & & \begin{tabular}{c} LNM, \\ advanced \\ TNN stage, \\ independent 3-year \\ OTB-231, \\ MDA-MB-468 cell lines & & & & \\ \end{tabular}  & \begin{tabular}{c} \\ \\ \\ \end{tabular}  & \ \begin{tabular}{c} \\ \\ \\ \end{tabular}  & \begin{tabular}{c} \\ \\ \\ \end{tabular}  \\ TINCR & [PERSON] et al. & BC patients; UACC812, & adjacent & & & \\  & (2023) & 4T1 \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline
**Studied** & **Authors, Year** & **Study Group** & **Study Material** & **IncRNA Change** & **Diagnostic Usefulness** & **References** \\ \hline ARNILA & [PERSON] et al. (2018) & TNBC patients (n = 88); MDA-MB-231, MDA-MB-231, cell lines; BALB/c & Cancerous tissue samples; BALB/c & Positive correlation with lung nodules & [88] \\  & (2018) & TDA-MB-436, HS578T & no-tumor samples; BALB/c nude & Impegulated samples; BALB/c nude & Impegulated indicators of PFS & \\ \hline Linc-ROR & [PERSON] et al. (2016) & BC patients (n = 142); MCF10A, SK-BR-3, MCF-7, Bcap-37, MDA-MB-231, T47D cell lines & Cancerous tissue samples; adjacent no-tumor samples & Impegulated & Strong correlation with LNM & [90] \\ \hline ANRIL, RNA-2 HFI1A-AS2, UCA1 & [PERSON] et al. (2017) & BC patients (n = 60), healthy volunteers (n = 40) & Serum; cancerous tissue samples; adjacent no-tumor samples & AUC: ANRIL cancerous & \\ ANRIL, RNA-2 HFI1A-AS2, UCA1 & [PERSON] et al. (2017) & BC patients (n = 60), healthy volunteers (n = 40) & Impegulated & Impegulated & 2 HFI1A-AS2 0.739, UCA1 0.817, combined & \\ \hline \hline \end{tabular}
\end{table} 
Table 1: _Cont._  
\begin{table}
\begin{tabular}{c c c c c c c} \hline \hline
**Studied** & **Authors, Year** & **Study Group** & **Study Material** & **lncRNA** & **Diagnostic** & **References** \\
**IncRNA** & & & & & **Change** & **Usefulness** & **References** \\ \hline \multirow{9}{*}{CCAT2} & \multirow{9}{*}{[PERSON] et al. (2020)} & \multirow{9}{*}{[PERSON] et al.